The FDA approves Eli Lilly’s (LLY) Tirzepatide drug for weight loss. The weight loss drug, Zepbound, it to be available by the end of 2023 and a one-month supply is to cost about $1,060. Zepbound should compete against Novo Nordisk’s Weogvy and Ozempic. Jenny Horne weighs in on this story. Tune in to find out more about the stock market today.